

Conclusions: The education provided by the nursing staff to potential donors in the first THADV program in Colombia is effective, well-regarded, and crucial for the program's long-term success and sustainability.

<https://doi.org/10.1016/j.aohep.2024.101644>

P-31 ACUTE LIVER FAILURE DUE TO WILSON'S DISEASE IN COSTA RICA: A LOOK AT GENETICS

Jorge Andres Herrera Corrales¹,
Francisco Hevia Urrutia², Danny Alvarado²,
Fernanda Vasquez Carit², Francisco Vargas Navarro²,
Jorge Eduardo Vargas Madrigal², Karina Hidalgo²,
Mildred Jimenez²

¹ CAJA COSTARRICENSE DEL SEGURO SOCIAL, San Jose, Costa Rica

² CCSS, San Jose, Chile

Conflict of interest: No

Introduction and Objectives: Acute liver failure (ALF) can be defined as a complex clinical syndrome characterized by coagulopathy, alteration in liver biochemistry and encephalopathy in a patient without underlying chronic liver disease. An exception occurs in patients with Wilson's Disease (WD) manifested precisely by ALF. Costa Rica is known as a country with a high incidence of WD, a pioneer in the study of the genetics of this disease, documenting more than 1,161 pathogenic variants. Taking advantage of the work of the genetics laboratory of the National Children's Hospital, we undertook the task of assessing the genetic spectrum of patients with FHA due to Wilson in the last 2 years in our country. **Objective:** To analyze and describe the genetic spectrum of acute liver failure due to WD in Costa Rica during the last two years.

Patients / Materials and Methods: Molecular Sequencing (Sanger NGS) for molecular confirmation, as well as MLPA techniques and Copy Number Variation Analysis (CNVs).

Results and Discussion: During the period (2022-2023), 86 patients with WD variants were identified, of which 30 had confirmatory genetics of the disease. 4 of them presented as having FHA, being managed with a liver transplant, and to this day all of them are alive. It was evident that 100% of the patients presented the c.3809A>G variant, with half of the patients being homozygous and the other half being c.3207C>A / c.3809A>G compound heterozygotes.

Conclusions: The c.3809A>G variant was found in all patients who presented ALF due to Wilson's disease in Costa Rica in the last 2 years. There is a lack of studies that assess the association between this variant and more aggressive presentations of the disease, however these results allow us to open a debate about the study of genetics as a predictor of ALF due to WD.

<https://doi.org/10.1016/j.aohep.2024.101645>

P-32 ACCESSIBILITY TO SEQUENTIAL SYSTEMIC TREATMENT AFTER TACE: IMPACT ON SURVIVAL IN A LATIN AMERICAN PROSPECTIVE COHORT

FEDERICO PIÑERO¹, Margarita Anders²,
Carla Bermúdez³, Diego Arufe⁴, Adriana Varón⁵,
Ana Palazzo⁶, Jorge Rodríguez⁷, Oscar Beltrán⁵,
Patricio Palavecino Rubilar⁸,
Leonardo Gomes da Fonseca⁹, Ezequiel Ridruejo¹⁰,

Norberto Tamagnone¹¹, Hugo Cheinquer¹²,
Nicolás Cortés Medina¹³, Juan Ignacio Marín¹⁴,
Estela Manero¹⁵, Federico Orozco Ganem²,
Jaime Poniachik⁸, Sebastián Marciano³,
Virginia Reggiardo¹¹, Manuel Mendizabal¹

¹ HOSPITAL UNIVERSITARIO AUSTRAL, Pilar, Argentina

² Hospital Alemán, Buenos Aires, Argentina

³ Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

⁴ Sanatorio Sagrado Corazón, Buenos Aires, Argentina

⁵ Fundación Cardioinfantil, Bogotá, Colombia

⁶ Hospital Padilla, Tucumán, Argentina

⁷ Hospital Central, Mendoza, Argentina

⁸ Hospital Clínico de la Universidad Chile, Santiago, Chile

⁹ Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Universidade São Paulo, Sao Paulo, Brasil

¹⁰ Centro de Educación Médica e Investigaciones

Clínicas (CEMIC), Buenos Aires, Argentina

¹¹ Hospital Centenario, Rosario, Argentina

¹² Hospital das Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul., Porto Alegre, Brasil

¹³ Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia

¹⁴ Hospital Pablo Tobón Uribe, Medellín, Colombia

¹⁵ Hospital Pablo Soria, San Salvador de Jujuy, Argentina

Conflict of interest: No

Introduction and Objectives: Stopping rules following transarterial chemoembolization (TACE), either tumor progression or "unTACEable" progression are needed. Avoiding liver decompensation after TACE may lead better access to systemic treatment and survival. These scenarios are unknown in our region. We aimed to evaluate accessibility to systemic therapy following TACE and its impact on survival.


Patients / Materials and Methods: A multicenter prospective cohort study conducted in Latin America, included HCC patients receiving TACE from May 15, 2018 to March 15, 2024. We excluded patients on the liver transplant waiting list, or Child Pugh C. Survival since first TACE was compared between groups accessing (A) and not accessing (no-A) to systemic therapy after TACE through Cox proportional hazard survival analysis, and adjusted treatment effect was further evaluated using a propensity score (PS) and inverse probability treatment weighting (IPTW).

Results and Discussion: From 258 receiving TACE, 188 were included after excluding 33 patients on the waiting list and 37 Child C (Table). Access to any systemic therapy was 46.8% (95% CI 39.5-54.2%), within a median time from TACE to first line of 9 months (range 3.7-17.0). In group A (n=88) systemic treatments following TACE were sorafenib 62.5%, atezolizumab + bevacizumab 31.8%, and lenvatinib 4.5%. Paradoxically, while presenting better liver function reserve, liver decompensation after TACE was more frequent in group A (7% vs 0%; P=0.004), without significant differences regarding median number of TACEs, modality, or tumor burden. Median survival since first TACE between groups was A 37.4 months vs no-A 29.8 months [HR 0.69 (95% CI 0.44-1.10), adjusted for the HAP score (Figure), which was unchanged after PS and IPTW.

Conclusions: In our region, less than half of HCC systemic treatment candidates acceded to sequential TACE-systemic therapy. Although not statistically significant, due to underpowered estimations, numerically higher survival was achieved with TACE-systemic therapies.

VARIABLE	Acceded systemic therapy n=88 (46.8%)	Not acceded systemic therapy n=100 (53.2%)	P values
Age, years ($\pm$ SD)	68 $\pm$ 9.5	65 $\pm$ 9.4	0.04
Gender, Male, n (%)	63 (71.6)	72 (72.0)	0.95
Cirrhosis, n (%)	76 (86.4)	95 (95.0)	0.04
Etiology of liver disease, n (%)			
Viral/non-viral	29 (32.9)/59 (67.0)	38 (38.0)/62 (62.0)	0.47
Hepatitis C	25 (28.4)	33 (33.0)	0.49
Metabolic associated steatotic liver disease	33 (37.5)	29 (29.0)	0.21
Alcoholic liver disease	6 (6.8)	12 (12.0)	0.79
Pre TACE characteristics			
Child Pugh A/B, n (%)	71 (80.7)/17 (19.3)	73 (73.0)/27 (27.0)	0.21
Prior decompensation, n (%)	17 (22.4)	13 (13.7)	0.14
ECOG 0-1, n (%)	87 (98.9)	96 (96.0)	0.22
Median total Bilirubin, mg/dl (IQR)	1.0 (0.7-1.5)	1.2 (1.0-1.6)	0.003
Median Albumin, g/dl (IQR)	3.8 (3.4-4.1)	3.5 (3.2-3.9)	0.008
Median INR, (IQR)	1.1 (1.0-1.3)	1.2 (1.0-1.3)	0.07
Mild/moderate Ascites, n (%)	3 (3.4)	8 (8.0)	0.31
Hepatic encephalopathy, n (%)	3 (3.4)	2 (2.0)	0.48
Median number of HCC nodules, (IQR)	2 (1-3)	2 (1-3)	0.61
Median serum AFP, ng/ml (IQR)	25.0 (7.4-147)	11.3 (4.2-159)	0.21
AFP $\geq$ 400 ng/ml, n (%)	11 (15.1)	16 (20.2)	0.40
BCLC before TACE, n (%)			
0	1 (1.1)	3 (3.0)	0.32
A	23 (26.1)	16 (16.0)	
B	55 (62.5)	70 (70.0)	
C	9 (10.2)	11 (11.0)	
HAP score before TACE, n (%)			
A	32 (36.4)	15 (15.0)	0.003
B	37 (42.0)	45 (45.0)	
C	13 (14.8)	28 (28.0)	
D	6 (6.8)	12 (12.0)	
TACE characteristics			
Median target lesion diameter, mm (IQR)	48.0 (35.5-60.0)	42.0 (31.5-55.0)	0.18
TACE modality, n (%)			
DEB-TACE	39 (47.0)	41 (44.6)	0.60
cTACE	44 (53.0)	49 (53.3)	
Other (TAE, chemoinfusion)	-	2 (2.2)	
Unknown	-	-	
Median number of TACEs	2 (2-3)	2 (1-3)	0.09
Post TACE outcomes			
ORR 1 st TACE	49 (55.7)	48 (48.0)	0.29
ORR last TACE	19 (24.7)	22 (31.4)	0.36
Liver decompensation, n (%)	7 (7.9)	- (0)	0.004

Comparison between patients acceding and not acceding to systemic therapies



Survival comparison between patients acceding and not acceding to systemic

<https://doi.org/10.1016/j.aohep.2024.101646>

P-33 COMBINATION OF FIB-4 SCORE AND D-DIMER TO PREDICT OUTCOME IN HOSPITALIZED COVID-19 PATIENTS

Fernanda Pozzobon Manhães¹,
Maria Chiara Chindamo², Renata Perez de Mello³,
Ronir Luiz Raggio³,
Maria Paula Cunha Fontes Raymundo⁴,
Julia Parente Gomes⁴, Taisa Garilha Melo⁴

¹ Hospital Barra Dor/IDOR, Rio de Janeiro, Brasil

² HOSPITAL BARRA DOR, Rio de Janeiro, Brasil

³ UFRJ, Rio de Janeiro, Brasil

⁴ REDE D'OR SÃO LUIS, Rio de Janeiro, Brasil

Conflict of interest: No

Introduction and Objectives: Identifying risk factors for poor outcomes is crucial for defining treatment strategies and allocating resources in COVID-19. The Fibrose-4 score (FIB-4) and D-dimer (DD) have emerged as prognostic markers; however, precise cutoff points and their combined use remain unstudied. **Objectives:** This study aimed to compare the individual and combined performance of FIB-4 and DD in predicting outcomes among COVID-19 patients.

Patients / Materials and Methods: Materials and Methods: From March to December/2020, hospitalized COVID-19 patients were evaluated regarding laboratory admission tests, chest CT scan, gender, age, lung involvement, ICU admission, hemodialysis, mechanical ventilation, and mortality. Optimal FIB-4 and DD cutoffs to predict in-hospital mortality, aiming to maximize sensitivity and specificity, were established. A sequential diagnostic strategy using both markers was subsequently evaluated.

Results and Discussion: Results and Discussion: Among 518 patients (61 $\pm$ 16 years, 64% men), the in-hospital mortality rate was 18%. FIB-4 showed superior performance in predicting mortality compared to DD (AUROC 0.76 vs. 0.65, p=0.003) and was chosen as